New Large Scale Pharmacogenomics Analysis by Translational Software Inc. Finds that 20% of Patients had Severe Drug-Gene Interaction Warnings for Their Current Medications


Patients with specific genetic variations are at increased risk from taking widely-prescribed medications

BELLEVUE, Wash.–(BUSINESS WIRE)–Translational Software®, Inc. (TSI), a leader in the intelligent use of genetic data for clinical decision support, undertook a large scale analysis to review the medication lists of 505,000 de-identified patients submitted to the company from 2013 to 2017 from its laboratory network to identify drug-gene interactions with four important pharmacogenes: CYP2C9, CYP2C19, CYP2D6 and SLCO1B1. Results of the analysis showed that 20 percent of patients had a pharmacogenetics (PGx) profile associated with a severe drug-gene interaction to drugs on their current medication list. An additional 48 percent of patients had a profile that caused a moderate drug-gene interaction.

“These results underscore the fact that patients with specific genetic variations are at increased risk from taking many widely prescribed drugs, such as common pain medications and cardiovascular agents”

Tweet this

According to the Centers for Disease Control and Prevention, adverse drug events cause more than one million emergency department visits and 280,000 hospitalizations each year. The CDC estimates that $3.5 billion is spent annually on excess medical costs to treat ADEs.

Read More